Genentech Charter Oak Partner

Connecticut Oncology Association

Home

About Us

Officers

Contact Us

Events

Corporate Partners

Membership

Member Application

Resources

Members Only

Corporate Sites

https://www.gene.com/

Medical Professionals Site

Contact in CT:

Emily Norman Bernard

Portfolio Field Reimbursement Manager

Cell: 860-324-6980

email: bernard.emily@gene.com

Important News and Information

Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment 12/8/2023

FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer

10/15/2021

FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer 05/29/2020

FDA Approves Genentech’s Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer 05/18/2020

Connecticut Oncology Association (CtOA)

c/o Dawn Holcombe

33 Woodmar Circle
South Windsor, CT 06074
(860) 305-4510

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Powered by Wild Apricot Membership Software